Русский
Management of lower urinary tract symptoms in patients with benign prostatic hyperplasia during COVID-19. results of an all-russian observational study “ATLANT”
DOI: https://dx.doi.org/10.18565/urology.2022.1.28-34
B.A. Neymark, A.I. Neymark, Ya.V. Yakovets, N.A. Nozdrachev, Kh.S. Ibishev, I.V. Kuzmin
1) Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation, Barnaul, Russia; 2) Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of Russia, Rostov-on-Don; 3) Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation», Saint Petersburg, Russia
Background. COVID-19 aggravates lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The optimal treatment regimen for patients with this disease during the COVID-19 pandemic is still under question.
Objectives. The aim of the All-Russian observational study of Afalaza in the Treatment of LUTS in pAtieNTs with BPH during COVID-19 (ATLANT) was to obtain additional data on the efficacy and safety of Afalaza in this patient group.
Methods. The study enrolled 73 men aged 46-65 years with LUTS and diagnosed BPH who suffered from COVID-19. All patients received Afalaza for 16 weeks. The dynamics of BHP indicators, erectile function, and quality of life were assessed after 4, 12, and 16 weeks of treatment.
Results. Patients with LUTS/BHP who suffered from COVID-19 had a decrease in the total IPSS score from 21.6±8.6 to 6.4±2.4 (-70.4%) points after 16 weeks of treatment. There was a direct correlation between COVID-19 duration (and beginning of therapy) and the severity of symptoms after Afalaza treatment. According to the subjective assessment of patients, there was a significant increase in the quality of life and erectile function after 16 weeks of treatment. 9 mild AEs were registered in 12.3% of patients and were unrelated
to the study drug.
Conclusions. Results show that Afalaza may be a perspective drug for the treatment of LUTS/BPH in patients with COVID-19 and be used for this urological disease in the current COVID-19 pandemic.
Objectives. The aim of the All-Russian observational study of Afalaza in the Treatment of LUTS in pAtieNTs with BPH during COVID-19 (ATLANT) was to obtain additional data on the efficacy and safety of Afalaza in this patient group.
Methods. The study enrolled 73 men aged 46-65 years with LUTS and diagnosed BPH who suffered from COVID-19. All patients received Afalaza for 16 weeks. The dynamics of BHP indicators, erectile function, and quality of life were assessed after 4, 12, and 16 weeks of treatment.
Results. Patients with LUTS/BHP who suffered from COVID-19 had a decrease in the total IPSS score from 21.6±8.6 to 6.4±2.4 (-70.4%) points after 16 weeks of treatment. There was a direct correlation between COVID-19 duration (and beginning of therapy) and the severity of symptoms after Afalaza treatment. According to the subjective assessment of patients, there was a significant increase in the quality of life and erectile function after 16 weeks of treatment. 9 mild AEs were registered in 12.3% of patients and were unrelated
to the study drug.
Conclusions. Results show that Afalaza may be a perspective drug for the treatment of LUTS/BPH in patients with COVID-19 and be used for this urological disease in the current COVID-19 pandemic.
About the Autors
Corresponding author: B.A. Neymark – Dr. Med. Sci., Professor of the department of urology Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation, Barnaul, Russia; е-mail: urologagmu@mail.ru
Similar Articles
